1) 一般社団法人日本透析医学会.慢性透析患者数の推移.http://docs.jsdt.or.jp/overview/pdf2014/p003.pdf(2016年3月30日アクセス)
2) 一般社団法人日本透析医学会.わが国の慢性透析療法の要約.http://docs.jsdt.or.jp/overview/pdf2014/p002.pdf(2016年3月30日アクセス)
3) 日本腎臓学会(編).CKD診療ガイドライン2012.東京:東京医学社;2012.
4) 三木健司,史 賢林,行岡正雄.骨粗鬆症における疼痛管理.骨粗鬆症治療2013;12:193-8.
5) Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468-74.
6) Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006;17:3223-32.
7) Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J kidney Dis 2000;36:1115-21.
8) Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women;Osteoporotic Fractures Research Group. Arch Intern Med 2007;167:133-9.
9) Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern med 2004;164:659-63.
10) Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012;7:810-9.
11) 日本透析学会.慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン.透析会誌2012;45:301-56.
12) 加藤謙一,加藤徳介,秋澤忠男.高カルシウム血症.腎と透析2006;61:89-93.
13) 山田真介,稲葉雅章.生活習慣病関連骨粗鬆症:CKD.Clin Calcium 2015;25:1329-38.
14) 吉矢邦彦,熊野晶文,原 章二・他.薬剤性の高カルシウム血症により腎機能増悪をきたしたCKD症例の検討.腎と骨代謝2009;22:73-7.
15) Ishani A, Blackwell T, Jamal SA, et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008;19:1430-8.
16) Adami S, Palacios S, Rizzoli R, et al. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 2014;17:273-84.
17) Melamed ML, Blackwell T, Neugarten J, et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective;a post-hoc analysis. Kidney Int 2011;79:241-9.
18) 濱野高行.CKD-MBDに伴う骨病変の薬物療法.The Bone 2015;29:163-9.
19) Mitchell DY, St Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000;49:215-22.
20) Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function:an analysis of the fracture intervention trial. J Bone Miner Res 2007;22:503-8.
21) Miller PD, Roux C, Boonen S, et al. safety and efficacy of risedronate in patients with aged-related reduced renal function as estimated by the Cockcroft and Gault method:a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105-15.
22) 骨粗鬆症の予防と治療ガイドライン作成委員会(編).骨粗鬆症の予防と治療ガイドライン2015年版.東京:ライフサイエンス出版株式会社;2015.
23) Geoffrey AB, Henry GB, Liang F, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2011;26:1829-35.
24) Daniel C, Katharina K, Till B, et al. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34):A pilot study. Kidney Blood Press Res 2010;33:221-6.
25) Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis Int 2007;18:59-68.